🎄Holiday Notice: Shipping for temperature-sensitive medications (Ozempic, Mounjaro, etc.) is paused. Service resumes Monday, Dec 29.
Generic Semaglutide Now Available!
We Ship To The U.S. Only
Call Toll Free:
Tirzepatide is a medication that is often sold under popular brand names Mounjaro and Zepbound. This medication is a GLP-1/GIP receptor agonist which has been approved for treating issues such as blood sugar control and helping obese patients manage their weight. Some patients may choose to buy compounded versions of this medication. This is oftentimes the case for patients who can not afford the branded and approved version of the medication or for patients trying to obtain the medication during a supply shortage. Some patients may also try to use compounded versions for cheaper off-label weight loss use. This article will cover what “compounded tirzepatide” means and how it is used. It will also cover the safety and regulatory concerns.
10% OFF
On Your First Order
Copy Code
MYRX10
10% OFF
On Your First Order
Copy Code
MYRX10
Compounded tirzepatide is a variation of the approved non-compounded medication that is made by Eli Lilly. These medications are produced by compounding pharmacies and are not considered approved products. They are often cheaper than the approved versions. However, they often contain some different ingredients and are not covered by insurance.
Compounded medications are those that have been created by a licensed compounding pharmacy as an alternative to a commercial medication that has already been approved. These medications are not technically approved even if it does contain the same active ingredient. However, they may be used in cases such as when the commercial versions are not readily available or suitable for a patient. This may be because of availability issues or patient allergies to the original medication. These compounded versions are also used for dose customizations.
This medication is also not considered to be a generic version of the medication since it is not approved by FDA under 505(j) of the FD&C Act. This means it does not undergo the same quality control processes and may not be as safe or effective to use. Consistency between these compounded versions may also vary by pharmacy.
Compounded versions are often made during times when the name-brand versions – like Monjaro and Zepbound in this case – and in short supply or patients have alternative requirements for the medication. They may be offered in vials and prefilled syringes or other formulations that differ from the standardized injection pens.
The compounded version of this medication started gaining popularity at the end of 2022 when the FDA declared a shortage of Mounjaro. The same happened a few months after the approval of Zepbound. This was caused by the high demand for tirzepatide. Additionally, the name-brand medications are often expensive – often costing between $1,000 and $1,300 without insurance. Compounded versions are usually hundreds of dollars cheaper and easier to access for off-label weight loss use. Compounded versions can also be made into non-traditional custom formulations – such as vials or prefilled syringes – that are not offered by the manufacturer.
This tirzepatide shortage was officially declared over in December 2024. Compounding may only be legal under certain shortage or patient-specific exemptions. Compounding is more limited legally when drug shortages are over and the original product once again becomes commercially available.
Compounded medications are only to be used by patients who can not have their needs met by the FDA-approved version. The effectiveness and quality of compounded versions cannot be guaranteed. The FDA warns patients about taking compounded tirzepatide since these medications do not undergo its safety review. The FDA says there have been 545 adverse events associated with the compounded version of this medication reported since July 31 alone.
Patients who take compounded medications are more likely to use a medication with impurities/contamination or dosing issues. Many dosing issues have been reported using these medications surrounding dosing – some instances leading to hospitalizations. The FDA also warns patients about fraudulent websites and pharmacies claiming to sell the medication. It is important for patients using the compounded medication to make sure they are only sourcing it from state-licensed compounding pharmacies that comply with USP <797> sterile compounding standards.
Mounjaro is the original brand-name tirzepatide medication that is used to help patients with type 2 diabetes manage their blood sugar levels. This medication is manufactured by Eli Lilly and has been officially approved by the FDA – meaning it adheres to strict quality and manufacturing control. This medication also comes in the form of standardized dosing pens. The list price is about $1,080 for this medication. However, some patients may have insurance coverage that may lower the price of this medication. Brand-name medications are also sometimes used off-label for purposes other than what they were FDA-approved for. Medications used like this are less likely to have insurance coverage.
Compounded versions of this medication are not approved or made by the same manufacturer. These are instead custom formulations made by a compounding pharmacy. The quality and effectiveness of these medications have not been through the same testing – and therefore are not guaranteed. There may also be some potential sterility or quality concerns. Dosing and forms of the medication may also vary. For example, some patients may be able to purchase the medication in the form of a multi-dose vial or prefilled syringe. The cost of these medications is often much cheaper than the name-brand version. However, cost and exact formulation vary by pharmacy. Insurance usually does not cover compounded versions.
Mounjaro comes in prefilled single-use pens and is prescribed to patients with a starting dose of 2.5 mg. This dose is strictly for treatment initiation and patients must take this dose of the medication for at least four weeks before their dose is increased to 5 mg. This dose may also be increased to 7.5 mg after four more weeks if additional glycemic control is needed. Doses for additional glycemic control can be increased in 2.5 mg increments up to 15 mg – the maximum dose. Patients must be taking each dose in between for at least four weeks each. The doses are accompanied by clear instructions and consistent formulation backed by FDA approval.
Doses of these medications may either mirror or differ from name-brand Mounjaro. Some patients may receive this medication in prefilled syringes. However, other patients may get their medication in the form of a vial that has multiple doses inside. The lack of standardized delivery increases the risk of dosing errors or inconsistency with these compounded medications.
Both of these medications technically include the same active ingredient. However, the compounded forms of the medication may not have the same precision in dose delivery as Mounjaro pens.
Compounded tirzepatide is made using the same active ingredient as Mounjaro. This means both medications have a lot of the same side effects. However, Mounjaro has a well-studied safety profile with predictable side effect rates from clinical trials. These studies and consistent dosing pens reduce the risk of patients developing side effects from accidentally misusing the medication.
Common side effects of these medications include:
Some rare but more serious side effects may also occur for patients taking these medications. These include:
Note: There is more limited data surrounding compounded medications and patients taking these versions risk of side effects may increase due to potential quality issues – such as sterility, concentration accuracy, or contaminants – from certain compounding pharmacies
Mounajaro is not technically approved for use in weight loss management. However, patients in the SURMOUNT-1 trial taking this medication often lost between 15% and 21% of their weight – depending on their dosage. Zepbound is the name-brand version of this drug that has been approved for weight loss use. Studies show that patients taking Zepbound lose an average of between 12% and 18% (depending on the specific trial). Results for all of this are well-documented with published peer-reviewed data.
No large-scale clinical trial data have been collected on the compounded versions of these medications. Efficacy should be similar if the compounded product matches the brand-name drug’s concentration and stability in theory. However, this can not be guaranteed. There is no clinical evidence supporting the amount of weight loss patients get from these medications on average. Only anecdotal reports of success exist. Results vary widely depending on the source and the specific compounds’ quality/formulation.
There has also been some risk evidence found about these pharmacies in the past. For example, the FDA released a warning in 2024 about one company called Fullerton Wellness LLC in Ontario, California. They warned that the company compounded injectable drugs like semaglutide and tirzepatide that were supposed to be sterile but may be contaminated. FDA and California regulators found that Fullerton Wellness used non-sterile ingredients and failed to sterilize them during inspection. This created a risk of serious infections or sepsis and the company had to stop its operations. The FDA then advised buyers to stop using any products they may have purchased from the company and contact their doctor.
The FDA no longer permits the sale of compounded tirzepatide from its compounding pharmacies at this time. This means availability is extremely limited. Patients should be aware that any website or seller claiming to offer compounded tirzepatide without a valid prescription may be unsafe or fraudulent.
Patients who do find a legitimate compounding pharmacy to use may present their prescription and have the pharmacy prepare custom doses in vials or syringes. Patients may be able to get these prescriptions written and fulfilled through telehealth services as well. Some of these websites may also offer direct pharmacy links.
Compounded tirzepatide can only be dispensed with a valid prescription from a licensed healthcare provider. Only state-licensed or PCAB-accredited compounding pharmacies should be used. These pharmacies are required to follow the sterile compounding guidelines outlined in USP <797>.
Medications prepared by compounding pharmacies are generally excluded from insurance plans. However, they are often much more affordable than the name-brand versions. Patients should be careful not to buy from unverified online vendors or social media ads. These are indicators of fake or unsafe websites that may be selling counterfeit medication or stealing personal information.
Purchasing compounded tirzepatide from unverified online vendors, social media ads, or unregulated medical spas is risky. These sources are not verified for safety and effectiveness before selling the compounded medication. This means patients may be exposed to unsafe products that can cause serious harm – like death or injury.
The FDA is still investigating many reports of adverse events occurring in association with faulty compounded medications. The reports include counterfeit products and mislabeled peptides. They also include other unsafe formulations and insanitary conditions.
Patients should only use state-licensed or PCAB-accredited compounding pharmacies and verify that the pharmacy follows USP <797> sterile compounding standards. They should also be cautious of any seller that does not require a valid prescription or does not list a physical address or contact information. Patients should avoid purchasing their medications from sellers who are selling their products through social media or suspicious websites that make unrealistic claims.
Compounded versions of medications have not been approved by the FDA like their name-brand counterparts. This means it has not been through the same level of safety testing and quality controls that guarantee safe and effective use for the patient purchasing the medication. It instead raises concerns about potential variability in drug purity, dosage accuracy, and quality control. This also means that there is a chance that these medications could lead to unpredictable and dangerous side effects. Ethical use of compounded tirzepatide is better justified only in specific situations – such as drug shortages or patient-specific dose needs that can not be met by Mounjaro.
Compounded tirzepatide is generally much more affordable than Mounjaro. This is especially the case for patients without insurance coverage or those seeking off-label use. This may make compounded medications more accessible for these groups of patients. However, it still does not mean that these medications are necessarily safe to use.
There are a few different groups of patients who may consider buying compounded tirzepatide. This includes patients who are:
These compounded medications are only appropriate for use by patients when they are prescribed and dispensed by a licensed medical provider and pharmacy.
Patients can try a few other alternatives that may be a better fit for them compared to compounded tirzepatide. This often includes other GLP-1 medications like semaglutide medications – such as Ozempic or Wegovy – and liraglutide medications – such as Victoza or Saxenda. Patients should talk to their doctor before making any decision about switching to an alternative medication. Each medication works a little differently and may be better suited for different groups of patients.
Some patients can also try making lifestyle changes to see how much progress they can make by doing so. This may include switching to a new diet or exercise routine. It may also include behavioral support
Patients who are looking for an alternative to make their medication more affordable may be able to get the name-brand version for cheaper by applying for manufacturer savings programs – which allow some patients to pay as little as $25 per month – or patient assistance programs. These programs can help commercially insured patients without government insurance support or low-income patients save hundreds of dollars on their medication each month.
Not always. Compounded versions are not FDA-approved and do not undergo the same quality checks – unlike Mounjaro or Zepbound. Safety depends on the pharmacy and whether it follows sterile compounding standards.
No. It is not made or tested by Eli Lilly – even if it uses the same active ingredient. This means dosing and ingredients may vary.
Brand-name Mounjaro and Zepbound often cost over $1,000 per month. Compounded versions are less expensive because they are not FDA-approved products and are usually not covered by insurance.
No. A prescription from a licensed healthcare professional is necessary. Be cautious of any website or seller offering it without one – these are often unsafe or fraudulent.
Insurance coverage for compounded drugs is usually limited or unavailable. Patients usually pay out-of-pocket – although the cost is often lower than brand-name versions.
The FDA has restricted compounding pharmacies from making tirzepatide now that supply of the brand-name versions has improved. Availability may be limited and patients should be careful to avoid unverified sources.
Compounded tirzepatide was originally made to combat low availability to patients due to high demand for the name-brand counterparts during a time of shortages. These compounded medications are also more affordable for patients who have to pay out-of-pocket. These medications are not officially approved. This means safety depends on the pharmacy and medical oversight. Patients should always consult a licensed healthcare provider before considering compounded medications.
Visit MyRx Outlet for affordable medications from Canada – including Mounjaro and other weight loss medications.
Aungst, C. (2025, June 2). Can’t Fill Your Mounjaro Prescription? Consider These 8 Mounjaro Alternatives. GoodRx. https://www.goodrx.com/mounjaro/alternatives-to-mounjaro?srsltid=AfmBOoqNzCTI5N0B0kBTeVbFFOugyQ39wbgiDUeOC8l03dUt8zJ5rGqd
Aungst, C. (2025, August 11). Is Compounded Tirzepatide Safe? 8 Things to Know About Mounjaro and Zepbound Knock-Offs. GoodRx. https://www.goodrx.com/classes/gip-receptor-glp-1-receptor-agonists/compounded-tirzepatide
Can you get tirzepatide from a compounding pharmacy? (2025, September 4). Drugs.com. https://www.drugs.com/medical-answers/you-tirzepatide-compounding-pharmacy-3575862/
Compounding and the FDA: Questions and Answers. (2025, September 16). U.S. Food And Drug Administration.
Compounding Pharmacy Accreditation (2025, August 12). ACHC. https://achc.org/pcab-compounding-pharmacy/
Compounded tirzepatide vs. Mounjaro. (2025, February 17). The Checkup. https://www.singlecare.com/blog/compounded-tirzepatide-vs-mounjaro/
FDA Approves New Medication for Chronic Weight Management. (2023, November 8). U.S. Food And Drug Administration.
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. (2025, September 25). U.S. Food And Drug Administration.
FDA warns patients and health care professionals not to use compounded drugs from Fullerton Wellness. (2024, November 1). U.S. Food and Drug Administration.
General Chapter 797. (n.d.). USP. https://www.usp.org/compounding/general-chapter-797
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038
Jackson, L. M., Parker, R. M., & Mattison, D. R. (2020, July 1). An overview of compounding. The Clinical Utility of Compounded Bioidentical Hormone Therapy – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK562881/
Sissons, B. (2025, April 29). Compounded Tirzepatide vs. Mounjaro. Healthline. https://www.healthline.com/health/drugs/compounded-tirzepatide-vs-mounjaro
The GLP-1 saga continues: FDA ends the Tirzepatide shortage: Frequently asked questions. (2025, January 24). FIDJ. https://fidjlaw.com/the-glp-1-saga-continues-fda-ends-the-tirzepatide-shortage-frequently-asked-questions/
Tirzepatide (subcutaneous route). (2025, July 1). Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/tirzepatide-subcutaneous-route/description/drg-20534045
Understanding the risks of compounded drugs. (2025, September 16). U.S. Food And Drug Administration.
USP General Chapter 797. (n.d.). https://www.usp.org/compounding/general-chapter-797
Written & Reviewed By
The MyRx Team
The MyRx Outlet team is a dedicated group of healthcare professionals and pharmacists dedicated to delivering up-to-date and accurate information on medications and key healthcare topics. With years of experience in the healthcare field, our team is passionate about supporting individuals in reaching their health and wellness goals through our articles.
The information provided here is for educational purposes only and is not intended to serve as medical advice, diagnosis, or treatment recommendations. It should not be taken as an endorsement of any specific medication or treatment. Individual health conditions and responses to treatment can vary greatly; therefore, this information should not be seen as a guarantee of safety, suitability, or effectiveness for any particular individual. Always consult with a healthcare professional for personalized medical advice and before making any decisions regarding your health or treatment plans.
Related Articles
Learn how to store Wegovy safely. Find out when to refrigerate, how long it lasts at room temperature, and tips for traveling with your medication.
Zepbound is now available from Canada. Order online with a valid prescription and save over 50% with secure U.S. delivery from MyRx Outlet.
What happens when you stop taking Mounjaro? Learn about weight regain, blood sugar changes, and how to manage side effects after discontinuing.
Share:
